Indian Covid-19 vaccine has 78% effectiveness against symptomatic infections, developer says – .

Indian Covid-19 vaccine has 78% effectiveness against symptomatic infections, developer says – .

Pharmaceutical company Bharat Biotech has announced that it has completed the final analysis of its Phase 3 clinical trials, which it has called the largest Covid-19 vaccine trial in India.

The trial involved 25,800 participants aged 18 to 98. Of these, 2,433 people were over 60 years of age and 4,500 had co-morbidities.

Bharat Biotech said the results revealed that Covaxin offered 65.2% protection against the Delta variant, which was first detected in India and is the dominant variant in the country.

Bharat Biotech President and CEO Dr Krishna Ella said the result “establishes the ability of India and developing countries to focus on innovation”.
“Covaxin will not only benefit the citizens of India, but will also go a long way in protecting the global community from the deadly (Covid-19),” said Balram Bhargava, director general of the Indian Council for Medical Research (ICMR), who co- developed the vaccine.

The two-dose injection of Covaxin was approved for restricted emergency use in India in January, ahead of the publication of preliminary results from the Phase 3 trial. It received emergency use authorization in 16 countries, including Brazil, the Philippines, Iran and Mexico, according to the company.

Hyderabad-based Bharat Biotech is in talks with the World Health Organization (WHO) to obtain emergency use authorization for its vaccine. If so, Covaxin would be the first vaccine developed in India to receive WHO clearance.

Bharat Biotech has faced controversy over the vaccine in the past. Earlier this year, more than a dozen participants in the Phase 3 trial in the slums of the Indian city of Bhopal told CNN they were unaware they were part of a clinical trial – au instead, they thought they were vaccinated.

Bharat Biotech, ICMR and Bhopal People’s Hospital, which conducted the trial, denied the wrongdoing.


Please enter your comment!
Please enter your name here